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Cancers can be recognized by the immune system, and the immune system may regulate and even
eliminate tumors. The development of checkpoint blocking antibodies, such as those directed
against cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1), have
demonstrated signiﬁcant recent promise in the treatment of an expanding list of malignancies.
While both CTLA-4 and PD-1 function as negative regulators, each plays a non-redundant role in
modulating immune responses. CTLA-4 attenuates the early activation of naïve and memory T cells.
In contrast, PD-1 is primarily involved in modulating T cell activity in peripheral tissues via interac-
tion with its ligands, PD-L1 and PD-L2. Unfortunately, not all patients respond to these therapies,
and evaluation of biomarkers associated with clinical outcomes is ongoing. This review will exam-
ine the efﬁcacy, toxicities, and clinical development of checkpoint blocking antibodies, including
agents already approved by the US Food and Drug Administration (anti-CTLA-4, ipilimumab) or in
development (anti-PD-1, PD-L1). Future studies will likely uncover new promising immunologic
checkpoints to target alone or in combination with other immunotherapeutic approaches, chemo-
therapy, radiotherapy, and small molecules.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The ﬁeld of immune-oncology has evolved over more than
120 years with several key milestones providing increasing evi-
dence for the role of the immune system in eradicating cancer.
One of the most signiﬁcant advances occurred in 1957 when
Thomas and Burnett suggested that tumor cells could evoke an im-
mune response and the concept of cancer immune surveillance
was introduced [1]. Cancers can be recognized by the immune sys-
tem, and under certain circumstances, the immune system may
control or even eliminate tumors [2,3]. Both innate and adaptive
immunity contribute to the recognition and rejection of malignant
cells [4–6]. Subsequent evidence that the immune system is in-
volved in tumor control [7] and the identiﬁcation of key molecules
that regulate cellular immune processes [8] have led to the devel-
opment of novel immunotherapeutic approaches for cancer
treatment.
Though a number of immunotherapeutic strategies have been
shown to increase the immune system’s ability to control cancer,
immunomodulatory antibodies that directly enhance the function
of T cells have been garnering signiﬁcant recent attention. These
agents are commonly called ‘‘checkpoint inhibitors’’ because they
block normally negative regulators of T cell immunity such ascytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death
receptor-1 (PD-1).
The clinical development of checkpoint blocking antibodies
such as ipilimumab (Bristol–Myers Squibb, Princeton, NJ), nivolu-
mab (Bristol–Myers Squibb, Princeton, NJ), and MK-3475 (Merck,
Whitehouse Junction, NJ) is built upon a foundation of basic re-
search into the mechanisms that regulate T cell activation. In the
‘‘two signal’’ model of T cell activation, antigen-speciﬁc T cell acti-
vation requires both T cell receptor (TCR) engagement (signal 1)
and a co-stimulatory signal B7-CD28 (signal 2) [9–13]. Subsequent
studies have supported this two-signal model and added layers of
complexity to its framework. It is now understood that a variety of
immunomodulatory signals, both costimulatory and coinhibitory,
are needed to orchestrate an optimal antigen-speciﬁc immune re-
sponse. Blockade of coinhibitory molecules such as CTLA-4, PD-1,
and lymphocyte-activation gene (LAG-3), or enhancement of co-
stimulatory molecules, such as glucocorticoid-induced TNF recep-
tor (GITR), OX40, and 4-1BB can amplify T cell responses against
tumors (Fig. 1) [3,13].
This review will focus on the clinical development of antibodies
that block the immunologic inhibitory molecules CTLA-4 and PD-1,
including agents that are already approved by the FDA (ipi-
limumab) or in various stages of clinical development (anti-PD-1,
anti-PD-L1) (Table 1). While both CTLA-4 and PD-1 function as
negative regulators, each plays a non-redundant role in modulat-
ing immune responses. CTLA-4, through engagement with its
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Fig. 1. Targeting immune checkpoints with CTLA-4 and PD-1 blocking antibodies in cancer immunotherapy. (a) The early immune response, ‘‘priming’’ phase, requires 2
signals for T cell activation, and occurs primarily within the lymph nodes. In the ﬁrst signal, T cells recognize antigens presented by the major histocompatibility complex
(MHC) on the surface of cancer cells through their T-cell receptor (TCR). A second signal is needed to complete T-cell activation via the B7 costimulatory molecules B7-1 and
B7-2. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is up-regulated shortly after T-cell activation and through a variety of mechanisms negatively regulates T cells. Anti-CTLA-4
antibodies, such as ipilimumab and tremelimumab, block this inhibitory signal, and thereby enhance antitumor activity. (b) Programmed death 1 (PD-1) inhibitory receptor
plays a more prominent role in modulating T cell activity in the peripheral tissues during the effector phase. PD-1 is expressed by T cells after antigen exposure, and its
ligation with PD-L1 and PD-L2 results in negative regulation of T cells in the tumor microenvironment. Blockade with antibodies to PD-1 or PD-L1 (e.g., Nivolumab and MK-
3475) results in the activation of T cells with speciﬁcity for the cancer. These mechanisms are additionally described in a recent review [91].
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activation of naïve and memory T cells. In contrast, PD-1 is primar-
ily involved in modulating T cell activity in peripheral tissues via
its interaction with PD-L1 and PD-L2. Lessons learned from treating
patients with CTLA-4 and PD-1 pathway-blocking antibodies are
likely to inform the clinical development of the next generation
of antibodies which affect T cell regulation by targeting a diversity
of coinhibitory and costimulatory molecules. Table 2 is a summary
of the published or presented trials investigating these various
checkpoint antibodies in cancer immunotherapy.2. CTLA-4 blocking antibodies: ipilimumab and tremelimumab
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a member of the
CD28:B7 immunoglobulin superfamily and is normally expressed
at low levels of the surface of naïve effector T-cells and regulatory
T cells (Tregs). After stimulation of a naïve T cell through the T cell
receptor (TCR), CTLA-4 localizes to the plasma membrane and
competes with CD28 for B7, ultimately turning off T cell receptor
signaling (Fig. 1) [14]. Antibodies that target CTLA-4 prevent the
attenuating function of CTLA-4 and consequently enhance T cell
function. CTLA-4 thereby serves as a physiologic ‘‘brake’’ on the
activated immune system to maintain normal immune homeosta-
sis [15].
Over 20 years of research have established the foundations for
the therapeutic potential of therapies targeting CTLA-4. CTLA-4
was ﬁrst described in 1987 as a member of the immunoglobulin
superfamily [16], and subsequent studies continued to describeits role in the inhibition of immune responses [14]. Studies in mice
suggested that functional CTLA-4 is essential for viability as CTLA-4
(/) mice die one month after birth from diffuse lymphoprolifer-
ation and autoimmunity [17]. Based upon this improved under-
standing of the importance of CTLA-4 as an immunologic
checkpoint, it was hypothesized that blocking CTLA-4 with mono-
clonal antibodies may be a strategy to enhance anti-tumor immu-
nity. In 1996, the ﬁrst preclinical report was published that
demonstrated CTLA-4 blockade with monoclonal antibody therapy
could result in tumor regressions in mice [18]. It appeared that
efﬁcacy of CTLA-4 blockade in preclinical experiments depended
upon the particular tumor model. Mice bearing the B16 melanoma
model were less sensitive to the effects of CTLA-4 blockade, and
therapeutic efﬁcacy was only achieved when CTLA-4 blockade
was combined with the granulocyte/macrophage colony-stimulat-
ing factor (GM-CSF)-producing vaccine [19]. This preclinical ﬁnd-
ing may be related to early suggestions of enhanced clinical
activity of CTLA-4 therapy in combination with GM-CSF [20].
Two antibodies that block CTLA-4, ipilimumab and treme-
limumab, have been evaluated in clinical trials, and ipilimumab
has been approved by the United States Food and Drug Administra-
tion for the treatment of advanced melanoma. Studies of these
agents have shown that both can result in durable control of
advanced cancer and, in the case of ipilimumab for patients with
advanced melanoma, overall survival can be improved. As these
agents prevent normal feedback inhibition of the immune
response, tolerance to other host tissues can be lost, leading to ad-
verse events which are often called immune-related adverse
events (irAEs).
Table 1
Summary table of checkpoint blocking antibodies in cancer immunotherapy.
Drug Antibody type Approved
for clinical
use
Notable side effects General stage of clinical development
Anti-CTLA-4 antibodies
Ipilimumab Fully human
IgG1 isotype
Y Diarrhea, colitis, fatigue, transaminitis, hypophysitis FDA approved for melanoma, Phase II and Phase III trial
ongoing for other multiple cancers
Tremelimumab Fully human
IgG2 isotope
N Diarrhea, fatigue, nausea, vomiting, anorexia, rash Phase II trials in mesothelioma and earlier phase studies for
other multiple cancers
Anti-PD-1 antibodies
Nivolumab Fully human
IgG4
N Pneumonitis, lymphopenia, fatigue, diarrhea,
hepatitis, renal insufﬁciency
Ongoing phase III trials in advanced melanoma and late
stage trials in other malignancies, including renal cell
carcinoma
MK-3475 Humanized
IgG4–kappa
isotype
N Pneumonitis, fatigue, thyroid problems Phase II/III trials in advanced melanoma and lung cancer
Pidilizumab Humanized
IgG1k isotype
N Pneumonitis, fatigue, diarrhea Phase II in hematologic malignancy, phase I/II in solid
tumors
Anti-PD-L1 antibodies
BMS-936559 Fully human
IgG4 isotype
N Fatigue, hyperglycemia, infusion reaction,
endocrinopathies, adrenal insufﬁciency and
myasthenia gravis
Phase I in multiple cancers
MEDI4736 Fully human
IgG1–kappa
N Still being evaluated Phase I in multiple cancers
MPDL33280A Fully human
IgG4 isotype
N Hyperglycemia, hypophysitis, pericardial effusion,
fatigue
Phase I in multiple cancers
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In two large phase III clinical trials of patients with advanced
melanoma, ipilimumab was shown to signiﬁcantly prolong overall
survival [21,22]. The ﬁrst phase III trial evaluated ipilimumab in
previously treated patients with melanoma and the second evalu-
ated ipilimumab for previously untreated patients.
2.1.1. Previously treated patients
676 Patients with unresectable stage III or stage IV melanoma
were randomized to receive ipilimumab alone, ipilimumab plus a
glycoprotein 100 (gp100) vaccine, or gp100 vaccine alone [21]. All
patients had previously received systemic treatment for advanced
melanoma. Ipilimumab (3 mg/kg) and/or gp100 vaccination wereTable 2
Published or presented trials investigating various checkpoint modulators in solid tumors
Study drug Disease n Ph Resu
Anti-CTLA-4 antibodies
Ipilimumab Melanoma 676 III Ipi +
Melanoma 502 III 36.2
17.9
12.2
Prostate 14 I 14%
RCC 61 II 10%
Tremelimumab CRC 47 II ORR
Gastric/ GEJ 18 II 1 PR
Melanoma 655 III 10.7
NSCLC 87 II 4.8%
Anti-PD-1 antibodies
Nivolumab Melanoma 107 I 31%
NSCLC 127 I ORR
RCC 34 I ORR
MK-3475 Melanoma 135 I 37%
Pidilizumab Hematologic malignancies 17 I 33%
Anti-PD-L1 antibodies
BMS-936559 Melanoma 52 I 17%
NSCLC 49 I 10%
Ovarian 17 I 6% O
RCC 17 I 12%
MPDL3280A Melanoma 45 I 26%given every three weeks for four doses. Overall survival was signif-
icantly increased in patients receiving ipilimumab (ipilimumab
plus gp100 versus gp100, median overall survival 10.0 versus
6.4 months, HR for death 0.68; ipilimumab alone versus gp100
alone 10.1 versus 6.4 months, HR 0.66, P < 0.001).
2.1.2. Previously untreated patients
In a subsequent second phase III trial, 502 patients with meta-
static melanoma previously untreated were randomly assigned to
dacarbazine with ipilimumab at a dose of 10 mg/kg or dacarbazine
with placebo [22]. All patients received dacarbazine (850 mg/m2
intravenously) every three weeks for eight cycles in the absence
of disease progression or signiﬁcant toxicity. Overall survival was
signiﬁcantly increased in patients assigned to dacarbazine with.
lts Refs.
gp100: 6% ORR; 14% S.D.; OS 10.0 vs 6.0 mo (gp100 arm) [21]
% at 1 year
% at 2 years
% at 3 years
[22]
pts with P50% PSA decline [80]
ORR [78]
2% (1 PR) [32]
after 8 cycles, 4/18 S.D. [31]
% ORR vs 9.8% (chemo arm) (ns); OS 12.6 vs 10.7 mo (ns) [29]
ORR vs 0% (supportive care); 21% 3 mo PFS vs 14% (ns) [31]
ORR; median OS 16.8 mo; 1-year OS 61% [59,92]
16%; median OS 9.6 mo [62,93]
29%; median OS >22 mo, 1 year OS 70% [92,94]
ORR; median PFS >7 mo; 77% had tumor shrinkage during study [60]
ORR [61]
ORR; 27% S.D. [62]
ORR; 10% S.D.
RR; 18% S.D.
ORR; 41% S.D.
ORR [63]
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versus 9.1 months). Survival rates at one, two, and three years con-
sistently favored treatment with ipilimumab (47% versus 36%, 29%
versus 18%, and 21% versus 12%, respectively).
2.2. Duration of response
A unique effect of therapeutic CTLA-4 blockade is the possibility
for remarkably durable tumor responses. Although only a minority
of patients achieves complete tumor regression, such responses
appear to be of prolonged duration in most cases. As an example,
177 patients were treated with ipilimumab between 2002 and
2005 in three early trials conducted by the National Institutes of
Health [23]. Fifteen patients (nearly 9%) achieved a complete re-
sponse (CR). All of these complete responses, except for one were
ongoing at the time of publication, with the longest lasting 99+
months.
2.3. Dosing and schedule
Ipilimumab has been studied at different doses and schedules of
administration. The approved dose of ipilimumab is 3 mg/kg by
intravenous infusion given every three weeks for four doses which
is based upon the results of the phase III trial in previously treated
patients [21]. Nonetheless, whether this is the optimal dose of ipi-
limumab is still being studied.
Three dose levels of ipilimumab were compared in a double-
blind phase II trial: 0.3, 3.0, and 10 mg/kg [24]. Patients were
treated every three weeks for four doses, with provision for main-
tenance treatment every 12 weeks in patients with an objective re-
sponse or stable disease. The objective response rate (complete
plus partial response) increased progressively with dose (0%,
4.2%, and 11.1% in the 0.3, 3, and 10 mg/kg groups, P = 0.002 for
trend). However, immune-related adverse events were also higher
in the 10 mg/kg group, with 27% versus 10% of patients requiring
treatment discontinuation in the 10 and 3 mg/kg arms,
respectively.
In order to deﬁnitively determine the optimal ipilimumab dose,
patients with advanced melanoma are being treated with 3 and
10 mg/kg of ipilimumab in an ongoing phase III trial which has
completed accrual (NCT01515189). The primary endpoint of the
trial is overall survival; results are pending. Additionally, it is un-
known whether maintenance ipilimumab administered every
12 weeks offers any beneﬁts beyond the initial ipilimumab induc-
tion course of four doses. Patients who experience clinical beneﬁt
from initial ipilimumab induction but who ultimately progress
may achieve additional beneﬁt from a repeat course of ipi-
limumab.[25] This is a treatment strategy that is widely used in
clinical management of patients with advanced melanoma.
2.4. Toxicities of ipilimumab: immune-related adverse events (irAEs)
and management
A wide range of immune-related adverse events (irAEs) have
been observed following treatment with ipilimumab. The most
common side effects include diarrhea, enterocolitis, hepatitis, der-
matitis, and endocrinopathies. In the ﬁrst phase III trial that dem-
onstrated an increase in overall survival, irAEs occurred in
approximately 60% of patients treated with ipilimumab; these typ-
ically did not occur until several weeks into therapy [21]. Overall,
severe or life-threatening (grade 3 or 4) toxicity was seen in 10–
15% of ipilimumab-treated patients, compared to 3% in those
receiving only gp100. The phase III trial used a dose of 3 mg/kg
of ipilimumab every three weeks. A somewhat higher incidence
of side effects was observed with an ipilimumab dose of 10 mg/
kg every three weeks in the randomized phase II trial that assessedthe effects of dose on activity and toxicity [24]. Treatment requires
interruption of ipilimumab and the use of corticosteroids, myco-
phenolate mofetil, or tumor necrosis factor (TNF)-alpha blockade
[26] and is based upon the severity of the observed toxicity. Algo-
rithms have been developed to aid in the management of these
side effects, but it is generally believed that prompt recognition
and early use of immunosuppressant therapy leads to resolution
without long-term sequelae.
2.5. Additional clinical consideration: opportunistic infections in
patients treated for irAEs
In refractory or severe IRAEs, patients require immunosuppres-
sion with ongoing steroids or TNF-alpha antagonists, which places
this emerging patient population at higher risk for opportunistic
infections. In our recent clinical experience, we have observed
cases of rare or opportunistic infections in patients treated with
novel immunotherapies who received immunosuppression for im-
mune-related toxicities, including pulmonary aspergillosis, zygo-
mycosis, Pneumocystis carinii pneumonia, Fournier’s gangrene,
and cytomegalovirus viremia. Optimal management requires a
multidisciplinary approach with a high index of suspicion to im-
prove clinical outcomes. Whether irAEs could be managed equally
effectively with alternative immunosuppression or whether pro-
phylactic antiviral and antibacterial therapies are beneﬁcial in this
unique population needs to be studied prospectively.
2.6. Ipilimumab in the adjuvant setting
Ipilimumab has been studied extensively in advanced mela-
noma, but the role of ipilimumab in the adjuvant setting after com-
plete surgical resection of high-risk melanoma, is currently
unclear. The European Organization for Research and Treatment
of Cancer (EORTC) is conducting a phase III trial in patients with
high-risk stage III disease (EORTC 18071, NCT00636168). In this
trial, following complete resection of high risk melanoma, patients
are randomly assigned to ipilimumab (dose 10 mg/kg every three
weeks for four cycles then every 12 weeks for a total of three years
treatment) or to placebo to determine whether ipilimumab pre-
vents disease recurrence. The trial has completed accrual and re-
sults are pending.
In addition, the Eastern Cooperative Oncology Group (ECOG) is
also evaluating ipilimumab in the adjuvant setting. Patients with
resected stage IIIB, IIIC, or IV disease are able to receive 3 or
10 mg/kg of ipilimumab versus standard high dose interferon-al-
pha. This study is currently recruiting patients (NCT01274338).
2.7. Tremelimumab
Tremelimumab (formerly Pﬁzer, New York, NY and currently li-
censed to MedImmune, Gaithersburg, MD) is another monoclonal
antibody directed again CTLA-4. Similarly to ipilimumab, treme-
limumab showed activity with durable responses in phase I and
II clinical studies [27,28]. Based upon these promising early results,
a phase III trial was conducted in which previously untreated pa-
tients were randomly assigned to either tremelimumab or chemo-
therapy [29]. Although there was a prolongation in response
duration among those treated with tremelimumab, the difference
in overall survival was not statistically signiﬁcant. It is possible
that the lack of a statistically signiﬁcant overall survival difference
was due to subsequent ipilimumab use in patients randomized to
initial chemotherapy in this trial. Further, this trial was the only
phase III trial comparing a CTLA-4 blocking antibody alone to che-
motherapy for patients with untreated advanced melanoma.
Tremelimumab has also been studied in phase II trials of refractory
patients with metastatic colorectal, gastric and esophageal cancers,
372 C. Kyi, M.A. Postow / FEBS Letters 588 (2014) 368–376and NSCLC [30–32] and additional investigations of tremelimumab
in combination with other anticancer therapies is expected.
3. Programmed death-1 antibodies: nivolumab, MK-3475, and
pidilizumab
Programmed death-1 (PD-1) is another key immune checkpoint
receptor expressed by activated T cells and is a promising therapeu-
tic target [33]. Although CTLA-4 and PD-1 both function as negative
regulators, they play unique non-redundant roles in the regulatory
pathway of activated T cells. PD-1 appears to play a more promi-
nent role inmodulating T cell activity in peripheral tissues via inter-
action with its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC). The
expression pattern of PD-L1, expressed broadly on hematopoietic
and non-hematopoietic tissues, and PD-L2, expressed on dendritic
cells, macrophages, mast cells, and B cells, supports this notion.
Like CTLA-4, PD-1 is a type 1 transmembrane protein of the Ig
superfamily. PD-1 was identiﬁed originally as a gene induced by a
T cell hybridoma undergoing apoptotic cell death [34]. When PD-
1 binds to its ligand, which in the case of PD-L1, is expressed on tu-
mor cells, T cell activity is attenuated which prevents these T cells
from rejecting the tumor. Since monoclonal antibodies can block
the interaction between PD-1 and PD-L1, they have been evaluated
as a strategy to augment the antitumor immune response.
The expression of PD-1 by tumor-inﬁltrating lymphocytes [35]
along with the expression of PD-L1 by numerous tumor types
[36] suggest that the pathway may be involved in immune evasion
by human cancers (Fig. 1). In particular, PD-L1 and to a lesser ex-
tent, PD-L2 are expressed on many human tumors, including uro-
thelial, ovarian, breast, cervical, colon, pancreatic, gastric cancers,
as well as melanoma glioblastoma and NSCLC [37–46]. In addition,
these molecules have also been detected on hematologic malig-
nancies, including Hodgkin lymphoma, primary mediastinal B cell
lymphoma, angioimmunoblastic T cell lymphoma, multiple myelo-
ma, acute myeloid leukemia, chronic lymphocytic leukemia, and
adult T cell leukemia/lymphoma [46–50]. Expression of PD-L1
has been correlated with prognosis in many of these malignancies,
supporting the hypothesis that PD-L1 expression may be a mecha-
nism for tumor immune evasion [42,51–53]. Together, these ﬁnd-
ings suggest that interrupting the PD-1:PD-L1/PD-L2 interaction
could be an effective anticancer therapy by blunting inhibition of
immune responses in the tumor microenvironment [54,55].
Preclinical murine models have also demonstrated the thera-
peutic potential of blocking the PD-1 axis [56]. Mice with a genetic
deﬁciency of PD-1 manifest enhanced immunity with phenotypes
characterized by autoimmune cardiomyopathy and a lupus-like
syndrome [57,58]. The less severe phenotype of PD-1 deﬁcient
compared to CTLA-4 deﬁcient mice parallels clinical results from
trials where preliminarily, PD-1 blockade appears to result in few
signiﬁcant clinical toxicities.
Based upon the preclinical rationale, several antibodies that in-
hibit the PD-1 pathway by blocking PD-1 or PD-L1 have been
developed for clinical use. This area is evolving rapidly, and though
we mention a number of agents in clinical development, we focus
on the agents for which clinical data are the most mature.3.1. Nivolumab
Nivolumab (previously, BMS-936558) is a fully humanmonoclo-
nal antibody that targets the PD-1 protein. This monoclonal anti-
body was evaluated in a phase I/II study in 296 patients with a
variety of heavily pretreated malignancies including non-small cell
lung cancer (NSCLC), prostate cancer, renal cell carcinoma (RCC),
and colorectal cancer (CRC), including 107 patients with advanced
melanoma [33].At the 2013 American Society of Clinical Oncology (ASCO) meet-
ing, updated efﬁcacy data from this study were presented with one
year of additional follow-up for the cohort of 107 patients with ad-
vanced melanoma [59]. The overall objective response rate was
31% for the entire melanoma cohort and an additional 7% had sta-
ble disease; there was no evidence for a dose response relationship,
although the dose selected for further clinical development as
monotherapy appears to be 3 mg/kg. The median duration of re-
sponse was 24 months. The median overall survival in this heavily
pretreated population was 17 months, and 43% of patients were
alive at two years.
In comparison to CTLA-4 blockade, rates of previously deﬁned
irAEs appeared to be less frequent. Nonetheless, grade 3 or 4 treat-
ment related adverse events were observed in 32 of 296 patients
(14%) enrolled in the study and appear to be somewhat distinct
from irAEs associated with CTLA-4 blockade. In particular, several
patients died with inﬂammatory pneumonitis, which has been
much less frequently described with CTLA-4 blockade. The exact
mechanism of pneumonitis induced by PD-1 blockade is unclear.
Three phase III trials are being conducted to evaluate the role of
nivolumab in patients with advanced melanoma. In NCT01721746,
patients who have progressed following ipilimumab and a RAF
inhibitor (if BRAF mutant) are being randomly assigned to receive
nivolumab or chemotherapy with either dacarbazine or carboplatin
pluspaclitaxel. In another trial, previouslyuntreatedpatientswill be
randomlyassigned tonivolumabordacarbazine (NCT01721772). Fi-
nally, in a third ongoing phase III trial, previously untreated patients
are being randomized to receive either ipilimumab, nivolumab, or
the ipilimumab and nivolumab (NCT01844505). The high durable
response rate of this agent has demonstrated early promise, but its
effects onoverall survival in comparison to standardapproacheswill
be known when these ongoing phase III trials are completed.
3.2. MK-3475
MK-3475 is humanized IgG4 anti-PD-1 monoclonal antibody
that has been extensively evaluated in both ipilimumab naïve
and previously treated patients. In a prospective non-randomized
large phase I study, 135 patients with advanced melanoma were
treated with MK-3475 on one of three dose schedules (10 mg/kg
every two weeks, 10 mg/kg every three weeks, or 2 mg/kg every
three weeks) [60]. No dose-limiting toxicity was identiﬁed within
this range, and promising clinical activity was noted.
The overall response rate at the initial reported analysis of the
135 patients was 38% using the standard response evaluation crite-
ria in solid tumors (RECIST) version 1.1 in the 117 patients with
measurable disease. The 10 mg/kg every two-week schedule ap-
peared most active with a 50% response rate, but this did not differ
signiﬁcantly from the other dosing regimens tested. Over 80% of re-
sponses were ongoing at the time of analysis, and the median pro-
gression-free survival was greater than 7 months. There was no
difference in response rate among those patients who had or had
not received prior ipilimumab. These data suggest that the PD-1
blocking antibodies have activity in patients with advanced mela-
noma who are refractory to treatment with ipilimumab.
Two randomized trials for patients with advanced melanoma
are accruing patients. One compares MK-3475 to chemotherapy
(NCT01704287) in patients who have previously received ipi-
limumab, and the other compares MK-3475 to ipilimumab
(NCT01866319) in treatment naïve patients.
3.3. Pidilizumab
Pidilizumab (previously CT-011, CureTech, Yavne Israel) is a
humanized IgG1 antibody initially tested in a phase I dose-escala-
tion, single-dose (0.2–6 mg/kg) study of 17 patients with
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(MTD) was not achieved, and the doses tested were well-tolerated.
Patient who achieved a response or a sustained stable disease to-
taled 33% of the study population, and one patient with follicular
lymphoma had a complete response. Based on these promising
results, additional clinical investigation of pidilizumab is being
conducted in a number of malignancies.
4. Programmed death ligand-1 antibodies
In addition to antibodies targeting PD-1, clinical activity has
been observed with several different anti-PD1-L1 monoclonal
antibodies.
4.1. BMS-936559
BMS-936559 is a fully human, PD-L1 speciﬁc IgG4 mAb. It binds
to PD1-L1, thus preventing its interaction with PD-1. BMS-936559
was tested in a dose escalation phase I/II study in pretreated pa-
tients with a variety of malignancies including NSCLC, melanoma,
CRC, RCC, ovarian cancer, pancreatic cancer, and breast cancer
[62]. The trial included 207 patients. Overall, potentially irAEs were
seen in 39% of patients. There were nine objective responses
among the 52 evaluable melanoma patients (17%). Five of these
had an objective response lasting at least one year, and six addi-
tional patients had stable disease that was maintained for at least
24 weeks. As with nivolumab, irAEs appeared less common with
PD-L1 blockade than with CTLA-4 blockade. In contrast to nivolu-
mab, no cases of pneumonitis were reported with BMS-936559.
This antibody was the ﬁrst published experience demonstrating
the clinical efﬁcacy of PD-L1 blockade.4.2. MPDL3280A
MPDL3280A (Genentech, San Francisco, CA) is another mono-
clonal antibody that binds to PD1-L1. Initial results of a phase I
dose escalation study were presented at the 2013 ASCO meeting
[63]. The dose escalation component of that study included 45 pa-
tients with advanced melanoma. An overall response rate of 29%
was reported, and 43% of patients were progression-free at
24 weeks. Additional clinical experience is being gained through
a dose expansion cohort in patients with advanced melanoma
and other malignancies. The Fc domain of this antibody has been
engineered to prevent antibody dependent cytotoxicity, but
whether this unique feature of this speciﬁc antibody is relevant
to its clinical activity requires ongoing clinical investigation.
4.3. MEDI3740
MEDI4736 (MedImmune, Gaithersburg, MD) is another PD-L1
antibody that is undergoing phase I clinical evaluation in a variety
of malignancies. As trials of this agent have only started more re-
cently, results of its safety and efﬁcacy are expected.
5. Understanding efﬁcacy of checkpoint blockade
5.1. Atypical patterns of radiographic response
Standard criteria for evaluating responses to anticancer agents
have been developed to promote objectivity and to facilitate com-
parisons across trials. One commonly used response criteria is the
RECIST criteria, which was developed based upon patterns of re-
sponses to standard chemotherapeutic agents. According to RECIST
and the closely related modiﬁed World Health Organization
(mWHO) criteria, an increase in tumor size and/or developmentof new lesions are deﬁned as progressive disease, typically impli-
cating that a change in therapy is warranted.
The patterns of radiographic response to treatment with the
checkpoint blocking antibodies described in this review, however,
may differ from patterns of response seen with standard chemo-
therapeutic agents in several important respects. First, when pa-
tients are treated with these immunomodulatory antibodies, they
may have an apparent transient worsening of disease, manifested
either by progression of known lesions or appearance of new le-
sions, before ultimate disease stabilization or tumor regression.
Secondly, responses can take an appreciably long time to become
apparent. The average time to achieve a complete response from
ipilimumab in one long-term study was 30 months [23]. Third,
some patients who do not meet criteria for objective response
can have prolonged periods of stable disease, and this is believed
to contribute to the beneﬁcial effects of ipilimumab on overall
survival.
Based on these observations, alternative response criteria,
termed the immune-related response criteria (irRC) were proposed
to capture these atypical responses. As an initial investigation of
this radiographic assessment approach, 487 patients treated on
three multicenter phase II clinical trials of ipilimumab were ana-
lyzed retrospectively [64]. In this analysis, it appeared that the irRC
better distinguished patients who had long-term survival than the
traditionally used mWHO response criteria. The concept of the irRC
is continuing to be evaluated and reﬁned [65], but prospective
evaluation in the context of a randomized controlled trial will be
necessary. Anecdotal immune-related responses have also been
described for patients treated with PD-1 and PD-L1 antibodies.
5.2. Biomarkers associated with clinical outcome
Studies have shown improved overall survival for patients with
advanced melanoma treated with ipilimumab and durable re-
sponses with the other agents, but unfortunately only a subset of
patients beneﬁt from treatment. Identifying patients most likely
to respond and/or develop side effects will be essential to optimiz-
ing use of these antibodies. Since these antibodies target the im-
mune system, biomarker investigations have largely focused on
investigating various immunologic parameters through monitor-
ing assays. The majority of putative biomarkers has been identiﬁed
in small, retrospective analyses, and prospective validation is an
area of active research.
5.3. Absolute lymphocyte count
Several studies suggest that the absolute lymphocyte count
(ALC) may be a pharmacodynamic marker for ipilimumab. In a
dose-ﬁnding phase II study of ipilimumab, patients receiving
10 mg/kg of ipilimumab seemed to have a greater rise in ALC than
patients receiving 3 mg/kg [24]. Small, single-center retrospective
analyses have also shown associations between ALC values at var-
ious timepoints and clinical outcomes following ipilimumab ther-
apy [66,67]. The association between ALC and clinical outcomes
was also found in patients with uveal melanoma treated with ipi-
limumab [68]. ALC increases while on ipilimumab therapy are an
intriguing possible biomarker because the ALC is readily available
from clinical laboratories. Further, since CTLA-4 blockade is associ-
ated with increased lymphocyte proliferation, an increase in ALC is
consistent with one of the mechanisms of action of CTLA-4
blockade.
5.4. Antigen-speciﬁc immune responses
Antigen-speciﬁc immune responses during CTLA-4 blockade
have been evaluated for a number of cancer-related antigens, such
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antigen, and prostate acid phosphatase. Most extensively, immune
responses to the cancer-testis antigen NY-ESO-1 have been charac-
terized to correlate with clinical activity. In a retrospective study of
144 ipilimumab-treated patients with melanoma, patients with
detectable titers of antibodies against NY-ESO-1 were more likely
to have achieved clinical activity with ipilimumab than patients
with no detectable NY-ESO-1 antibody titers [69]. Patients with
additional CD8+ T cell reactivity against NY-ESO-1 were shown
to be even more likely to achieve clinical activity. Whether an im-
mune response to NY-ESO-1 is just a surrogate of a functional anti-
tumor immune system or a direct mediator of the antitumor
activity of ipilimumab therapy remains unknown. Likely many
additional mediators are involved. Whether NY-ESO-1 vaccination
in combination with ipilimumab is a safe and efﬁcacious therapeu-
tic strategy for patients whose tumors express NY-ESO-1 is being
evaluated (NCT01810016).
5.5. Inducible co-stimulator
Inducible co-stimulator (ICOS) is a costimulatory molecule ex-
pressed on the surface of T cells and is thought to play an especially
important role in T cell survival, proliferation, and generation of
memory [70]. In bladder cancer patients treated with neoadjuvant
ipilimumab, ICOS expression was correlated to clinical activity, as
it was upregulated on tumor-inﬁltrating T cells. In a small retro-
spective analysis of melanoma patients treated with ipilimumab,
increased frequency of CD4+ ICOS high T cells, sustained over a
period of 12 weeks correlated positively with increased overall
survival [71].
5.6. Future directions of biomarker analyses
Ongoing investigations into biomarkers associated with clinical
beneﬁt to immune checkpoint inhibitors may ultimately enable
clinicians to select the most appropriate immunotherapeutic strat-
egy for an individual patient. At present, however, no biomarker
associated with clinical outcomes described herein has yet been
developed to a sufﬁcient degree to enable physicians to select par-
ticular patients for one speciﬁc immunotherapeutic strategy. Pro-
spective investigation of several of these biomarkers is ongoing.
In particular, analysis of PD-L1 as a pre-treatment biomarker for
PD-1 outcomes is being evaluated in ongoing phase II and III stud-
ies (NCT01927419 and NCT01844505) to see whether it correlates
with clinical outcomes to anti-PD-1 antibody therapy and other
immunotherapy strategies. It is quite possible that immunologic
biomarkers will not be used for selecting patients at baseline most
likely to respond to immunotherapy but instead may serve as
ongoing measures of the expected pharmacodynamic effects of
therapy which may be used to inform ongoing dosing.
6. Checkpoint blockade in other tumor types
While evaluations of immunotherapy have largely focused on
melanoma (because of durable responses noted historically with
immunotherapy, such as interleukin-2) [72], there is now growing
evidence that this approach is also applicable to other malignan-
cies, including prostate, lung, pancreatic, hepatocellular carcinoma
and hematologic malignancies [33,73–78]. In a phase I study
evaluating BMS-936559, evidence of clinical activity was seen in
patients with NSCLC, RCC, and melanoma, and one patient with
ovarian cancer also had a response [62]. Patients with prostate can-
cer have also been reported to have objective radiographic and bio-
chemical responses with ipilimumab [79,80]. Future studies are
ongoing and necessary to elucidate the diversity of responses inthe spectrum of tumor types, and evaluate whether checkpoint
blocking antibodies have additional clinical beneﬁts.
7. Future directions: combination therapies
7.1. Combined anti-CTLA plus PD-1 blockade
The combined administration of anti-CTLA-4 immunotherapy
with ipilimumab plus anti-PD-1 immunotherapy with nivolumab
was recently described to have an acceptable safety proﬁle and a
preliminarily high response rate in the small group of patients
evaluated [81]. Out of all patients treated with both ipilimumab
and nivolumab, 40% had an objective response. Though grade 3
or 4 irAEs were described in 53% of patients, many were asymp-
tomatic laboratory abnormalities of unclear signiﬁcance and most
resolved without signiﬁcant sequelae.
Additional clinical experience and longer follow-up will be re-
quired to determine whether combination immune checkpoint
inhibition offers signiﬁcant beneﬁts over sequential use of each
checkpoint antibody alone. A phase III trial is studying the combi-
nation of nivolumab plus ipilimumab compared with each of these
checkpoint inhibitors as a single agent (NCT01844505). Sequential
therapy with each agent used individually is also being investi-
gated in a phase II trial (NCT01783938). Additional investigation
of this combination approach is expected in multiple additional
malignancies.
7.2. Ipilimumab plus granulocyte–macrophage colony-stimulating
factor
The addition of granulocyte–macrophage colony-stimulating
factor (GM-CSF) to ipilimumab was studied in a phase II trial con-
ducted by Eastern Cooperative Oncology Group (ECOG). In this
trial, 245 patients with advanced melanoma were randomly as-
signed to ipilimumab plus GM-CSF or ipilimumab alone [20]. Ipi-
limumab was given at a dose of 10 mg/kg every three weeks for
four cycles, followed by maintenance every 12 weeks. GM-CSF
(250 micrograms/day subcutaneously) was given on days 1–14 of
each 21 day cycle. At a median follow-up of 13 months, there
was no difference in the objective response rate with or without
GM-CSF (15.5% and 14.8%, respectively) nor was there a signiﬁcant
difference in progression-free survival (34.0% versus 29.6% at
6 months, hazard ratio [HR] 0.92, 95% CI 0.69–1.23). However,
overall survival was signiﬁcantly improved by the addition of
GM-CSF (median 17.5 versus 12.7 months, one-year survival rates
69 versus 53%, HR 0.64, P = 0.014). The addition of GM-CSF also re-
sulted in a signiﬁcant reduction in the incidence of high grade ad-
verse events, particularly related to pulmonary and
gastrointestinal toxicity. It is important to consider that this trial
used a higher dose of ipilimumab (10 mg/kg) than is currently
approved for commercial use (3 mg/kg) and that maintenance
therapy was also included. The clinical implications of these results
will require further study and conﬁrmation but is consistent with
preclinical evidence showing efﬁcacy of combining CTLA-4 block-
ade with GM-CSF [19].
7.3. Ipilimumab plus radiation therapy
The abscopal effect describes the phenomenon of tumor regres-
sion at sites distant from the primary site of radiotherapy. This ef-
fect could be caused by radiation-induced antigen and cytokine
release, which subsequently potentiates a systemic immune re-
sponse against the tumor. Case studies have provided anecdotal
evidence of the abscopal effect, along with immunologic correlates
[82,83]. In-depth immune monitoring of one patient treated with
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responses to various antigens, as well as a decrease in an immuno-
suppressive cellular population during an abscopal effect [82].
The combination of radiotherapy plus immunotherapy is
currently being prospectively evaluated (NCT01703507,
NCT01497808, NCT01565837, NCT01689974). Combinations with
alternative modalities of local control – for example with cryoabla-
tion or electrochemotherapy – are also being investigated
(NCT01502592, NCT01642290) [84].
7.4. Ipilimumab plus small molecule, targeted therapy
Signiﬁcant preclinical data suggest that small molecule thera-
pies directed against oncogenic signaling pathways such as those
that interact with the mitogen activated protein kinase pathway
in melanoma (BRAF mutant melanoma) have important immuno-
logic effects [85–89]. Investigating whether these targeted thera-
pies enhance the effects of immunotherapy, therefore, has been
an area of great interest. Unfortunately, a phase I trial combining
the BRAF inhibitor, vemurafenib (Roche, Basel, Switzerland) with
ipilimumab was closed early due to hepatotoxicity [90]. Careful
consideration into the safest and most thoughtful way of further
clinically evaluating the combination of small molecule cancer
therapies with immunotherapy will be necessary. Ongoing trials
will continue to shed light on this therapeutic strategy
(NCT01767454).
8. Conclusions
Immunologic checkpoints are an essential component of the
immune system, and manipulation of the effects of these natural
checkpoints with therapeutic antibodies may control or even elim-
inate tumors. Antibodies that block inhibitory pathways, such as
those directed against CTLA-4 and PD-1 have been developed for
clinical use. These checkpoint-blocking antibodies are revitalizing
interest in solid tumor immunotherapy and have resulted in prom-
ising clinical outcomes, exempliﬁed by the FDA approval of ipi-
limumab in 2011. Lessons learned from studies of CTLA-4 and
PD-1 blockade provide a foundation for the further development
of checkpoint blocking antibodies. Continued research into the
understanding of biomarkers associated with response and the un-
ique adverse effect proﬁles of these agents will ultimately lead to
improved patient care. While evaluations of immunotherapy have
largely focused on melanoma, there is now growing evidence that
this approach is also applicable to other malignancies. Future stud-
ies should likely uncover new promising immunologic check-
points, which can be targeted alone or in combination with other
immunotherapeutic approaches, chemotherapy, radiotherapy,
and small molecules that target oncogenic pathways.
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